Alteration of AKAP220, an upstream component of the Rb pathway, in oral carcinogenesis

International Journal of Cancer

Volumn 116, Issue 5, 2005, Pages 813-819

  Garnis, Cathie ^a   Rosin, Miriam P ^a,b   Zhang, Lewei ^c   Lam, Wan L ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

13q14; AKAP220; Oral premalignant lesion; Progression; Rb

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; DIACYLGLYCEROL KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN AKAP220; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL CYCLE; CHROMOSOME 13Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTIG MAPPING; CONTROLLED STUDY; DNA FINGERPRINTING; DYSPLASIA; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LEUKOPLAKIA; MOUTH CANCER; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOM AMPLIFIED POLYMORPHIC DNA;

BASE SEQUENCE; CARRIER PROTEINS; CHROMOSOME MAPPING; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 13; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR SEQUENCE DATA; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 23244458991     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21065     Document Type: Article

References (43)

1. Shah JP. Head and neck surgery for the surgical oncologist. Ann Surg Oncol 1995;2:374-5.
2. Yokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
3. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994; 73:187-90.
4. Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent 2001;49:72-82.
5. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989;17:691-4.
6. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, Fu KK, Cooper JS, Yokes EE, Chamberlain RM, Williams B, Pajak TF, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823-9.
7. Ah-See KW, Cooke TG, Pickford IR, Soutar D, Baimain A. An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res 1994;54:1617-21.
8. Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM, Sidransky D. Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994;54:1152-5.
9. Hermsen MA, Joenje H, Arwert F, Braakhuis BJ, Baak JP, Westerveld A, Slater R. Assessment of chromosomal gains and losses in oral squamous cell carcinoma by comparative genomic hybridisation. Oral Oncol 1997;33:414-8.
10. Wolff E, Girod S, Liehr T, Vorderwulbecke U, Ries J, Steininger H, Gebhart E. Oral squamous cell carcinomas are characterized by a rather uniform pattern of genomic imbalances detected by comparative genomic hybridisation. Oral Oncol 1998;34:186-90.
11. Okafuji M, Ita M, Oga A, Hayatsu Y, Matsuo A, Shinzato Y, Shinozaki F, Sasaki K. The relationship of genetic aberrations detected by comparative genomic hybridization to DNA ploidy and tumor size in human oral squamous cell carcinomas. J Oral Pathol Med 2000;29:226-31.
12. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res 1992;52:5997-6000.
13. Lese CM, Rossie KM, Appel BN, Reddy JK, Johnson JT, Myers EN, Gollin SM. Visualization of INT2 and HST1 amplification in oral squamous cell carcinomas. Genes Chromosomes Cancer 1995;12:288-95.
14. Califano J, van der Riet P, Westra W, Nawroz H, dayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92.
15. van Heerden WF, Swart TJ, Robson B, Smith TL, Engelbrecht S, van Heerden MB, van Rensburg EJ, Huebner K. FHIT RNA and protein expression in oral squamous cell carcinomas. Anticancer Res 2001;21:2425-8.
16. Yakushiji T, Noma H, Shibahara T, Arai K, Yamamoto N, Tanaka C, Uzawa K, Tanzawa H. Analysis of a role for p16/CDKN2 expression and methylation patterns in human oral squamous cell carcinoma. Bull Tokyo Dent Coll 2001;42:159-68.
17. Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, El-Naggar A, den Hollander P, Liu D, Hittelman WN, Hong WK. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 2001;7:3127-34.
18. Piboonniyom SO, Timmermann S, Hinds P, Munger K. Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity. Oral Oncol 2002;38:179-86.
19. Li X, Lee NK, Ye YW, Waber PG, Schweitzer C, Cheng QC, Nisen PD. Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst 1994; 86:1524-9.
20. Ogawara K, Miyakawa A, Shiba M, Uzawa K, Watanabe T, Wang XL, Sato T, Kubosawa H, Kondo Y, Tanzawa H. Allelic loss of chromosome 13q14.3 in human oral cancer: correlation with lymph node metastasis. Int J Cancer 1998;79:312-7.
21. Yoo GH, Xu HJ, Brennan JA, Westra W, Hruban RH, Koch W, Benedict WF, Sidransky D. Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 1994;54:4603-6.
22. Maestro R, Piccinin S, Doglioni C, Gasparotto D, Vukosavljevic T, Sulfaro S, Barzan L, Boiocchi M. Chromosome 13q deletion mapping in head and neck squamous cell carcinomas: identification of two distinct regions of preferential loss. Cancer Res 1996;56:1146-50.
23. Gupta VK, Schmidt AP, Pashia ME, Sunwoo JB, Scholnick SB. Multiple regions of deletion on chromosome arm 13q in head-and-neck squamous-cell carcinoma. Int J Cancer 1999;84:453-7.
24. Sanchez-Cespedes M, Okami K, Cairns P, Sidransky D. Molecular analysis of the candidate tumor suppressor gene ING1 in human head and neck tumors with 13q deletions. Genes Chromosomes Cancer 2000;27:319-22.
25. Partridge M, Pateromichelakis S, Phillips E, Emilion G, Langdon J. Profiling clonality and progression in multiple premalignant and malignant oral lesions identities a subgroup of cases with a distinct presentation of squamous cell carcinoma. Clin Cancer Res 2001;7: 1860-6.
26. Nishida N, Fukuda Y, Komeda T, Ho T, Nishimura T, Minata M, Kuno M, Katsuma H, Ikai I, Yamaoka Y, Nakao K. Prognostic impact of multiple allelic losses on metastatic recurrence in hepatocellular carcinoma after curative resection. Oncology 2002;62:141-8.
27. Sun PC, el-Mofty SK, Haughey BH, Scholnick SB. Allelic loss in squamous cell carcinomas of the larynx: discordance between primary and metastatic tumors. Genes Chromosomes Cancer 1995;14:145-8.
28. Wada T, Louhelainen J, Hemminki K, Adolfsson J, Wijkstrom H, Norming U, Borgstrom E, Hansson J, Sandstedt B, Steineck G. Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade. Clin Cancer Res 2000; 6:610-5.
29. Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, van Der Kwast TT, Schroder FH, Tanke HJ, van Dekken H. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol 2001;158:399-406.
30. Vizcarra E, Martinez-Climent JA, Benet I, Marugan I, Terol MJ, Prosper F, Marco J, Sanchez D, Ferrandez A, Tormo M, Sarsotti E, Ferrer R, et al. Identification of two subgroups of mantle cell leukemia with distinct clinical and biological features. Hematol J 2001; 2:234-41.
31. Allen JE, Hough RE, Goepel JR, Bottomley S, Wilson GA, Alcock HE, Baird M, Lorigan PC, Vandenberghe EA, Hancock BW, Hammond DW. Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. Br J Haematol 2002;116:291-8.
32. Kitamura E, Su G, Sossey-Alaoui K, Malaj E, Lewis J, Pan HQ, Hawthorn L, Roe B, Cowell JK. A transcription map of the minimally deleted region from 13q14 in B-cell chronic lymphocytic leukemia as defined by large scale sequencing of the 650 kb critical region. Oncogene 2000;19:5772-80.
33. Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ, Croce CM. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 2001;61:6640-8.
34. Wolf S, Mertens D, Schaffner C, Korz C, Dohner H, Stilgenbauer S, Lichter P. B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Hum Mol Genet 2001;10:1275-85.
35. Mabuchi H, Fujii H, Calin G, Alder H, Negrini M, Rassenti L, Kipps TJ, Bullrich F, Croce CM. Cloning and characterization of CLLD6, CLLD7, and CLLD8. novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res 2001;61:2870-7.
36. Zhang L, Michelsen C, Cheng X, Zeng T, Priddy R, Rosin MP. Molecular analysis of oral lichen planus. A premalignant lesion? Am J Pathol 1997;151:323-7.
37. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlorofonn extraction. Anal Biochem 1987;162:156-9.
38. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND, Zhang L. Use of allelic loss to predict malignant risk for low-arade oral epithelial dysplasia. Clin Cancer Res 2000;6:357-62.
39. Schillace RV, Scott JD. Association of the type 1 protein phosphatase PP1 with the A-kinase anchoring protein AKAP220. Curr Biol 1999;9:321-4.
40. Schillace RV, Voltz JW, Sim AT, Shenolikar S, Scott JD. Multiple interactions within the AKAP220 signaling complex contribute to protein phosphatase 1 regulation. J Biol Chem 2001;276:12128-34.
41. Rubin E, Tamrakar S, Ludlow JW. Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control. Front Biosci 1998;3:D1209-19.
42. Oliver CJ, Shenolikar S. Physiologic importance of protein phosphatase inhibitors. Front Biosci 1998;3:D961-72.
43. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997;237:1-6.